A 61-year-old patient with alcohol use disorder (AUD) was referred for suspicion of sleep apnea syndrome (SAS). He had incurred three road accidents attributed to sleepiness over the previous year, shortly after initiation of high-dose (100 mg b.i.d.) treatment with baclofen, a molecule increasingly used in the management of AUD. Polysomnography revealed a severe central SAS (CSAS) with an apnea-hypopnea index (AHI) of 81.6/h. Baclofen was suggested as a possible
Introduction
Over the past 10 years, there has been widespread interest in the role of the GABA B receptor in the control of alcohol use-related behaviors. In this context, baclofen, a GABA B agonist, has been increasingly used at high doses in the management of alcohol use disorder (AUD). However, little is known about the potential effects of this offlabel treatment on breathing physiology during sleep.
Case Report
A 61-year-old patient with AUD was referred to the sleep laboratory for suspicion of sleep apnea syndrome (SAS) because of snoring, poor sleep quality and sleepiness [Epworth Sleepiness Scale (ESS) score 11/24] . Over the previous year, he had incurred three road accidents attributed to sleepiness. It seemed likely that these events were related to sleep-disordered breathing. For 2 years, he had been on high-dose baclofen, which helped him to decrease alcohol consumption from 140-160 to 40-60 g/day. He was treated only with baclofen (100 mg b.i.d.) when we performed a first polysomnography (PSG) ( fig. 1 ) .
Respiratory parameter measurements and event scoring were performed according to the current recommendations [1] . The sensors used were an oronasal thermal sensor and a nasal pressure transducer for airflow as well as calibrated dual thoracoabdominal respiratory inductance plethysmography belts for respiratory effort. Oxygen saturation was obtained by continuous pulse oximetry, and ventilatory status by continuous transcutaneous capnography (Ptc CO 2 ). PSG revealed a severe central SAS (CSAS) with an apnea-hypopnea index (AHI) of 81.6/h ( table 1 ). Ptc CO 2 was normal, with no argument for hyper-or hypoventilation according to the current definitions [1] . The clinical examination was unremarkable and showed no sign of neurological or cardiac disease that could explain the presence of CSAS. The chest auscultation results and oxygen saturation were normal. The body mass index was 24.4. An echocardiography showed no sign of left or right ventricular dysfunction, and a normal left ventricular ejection fraction. A cerebral CT scan was normal. We thus considered baclofen as a possible cause of CSAS.
A few weeks after its withdrawal, the consumption of alcohol, a known risk factor for obstructive SAS, increased again to 140-160 g/day. A second PSG ( fig. 1 ) showed a shift toward a typical severe obstructive SAS (AHI 43.9/h) ( table 1 ). The patient was initiated on continuous positive airway pressure (CPAP) treatment (REMstar auto, Respironics) in the auto-adjusting mode (autocPAP, with a pressure range of 5-15 cm H 2 O). Two months after CPAP initiation, the patient noted a marked improvement in symptoms (ESS score 6/24). The reports downloaded from the device showed a satisfactory compliance (7 h/night) and a normalization of the AHI (1.9/h; mean pressure 7.0 cm H 2 O) without persistent central events. At the 6-month clinical follow-up, the patient's comfort and compliance (4.3 h/night) had decreased, and the mean pressure applied had increased to 9.6 cm H 2 O. Moreover, the CPAP download reports showed an increase in AHI (20.8/h) with detection of a Cheyne-Stokes respiration pattern ( fig. 2 ). The patient acknowledged that, unbeknown to us, he had gone back on baclofen (50 mg b.i.d.) and had decreased alcohol consumption (60-80 g/day). The clinical examination was unchanged. The 
Discussion
This case report strongly suggests a causal relationship between high-dose baclofen and CSAS. The occurrence of central apneas was most probably baclofen induced, as withdrawal of this drug resulted in their disappearance, while its reintroduction reinstalled a severe CSAS under CPAP. Moreover, the patient had no cardiac or neurological disease and took no other medication with documented side effects on sleep-related breathing. Alcohol consumption was negatively correlated with central apneas, arguing against a direct causal relationship, even if a potential influence of alcohol cannot be ruled out with certainty. Indeed, the patient was still using alcohol together with baclofen treatment (40-60 g/day), which may have increased his vulnerability to sleep-related breathing disorders. Finally, CSAS was probably not generated by CPAP therapy (treatment-emergent CSAS), as the use of auto-CPAP without baclofen during several weeks was characterized by a perfect control of respiratory events.
The main known side effects of baclofen, a GABA B agonist, are sedation and excessive sleepiness. Animal and human studies have demonstrated that baclofen significantly prolongs total sleep time, while sleep fragmentation is reduced [2] [3] [4] . In a double-blind, placebo-controlled, cross-over study of a single dose of baclofen (25 mg) administered before sleep to 10 snoring subjects with mild-to-moderate sleep-disordered breathing (AHI , with an insignificant trend toward more apneas or hypopneas [2] . It was hypothesized that the reduction in Sp O 2 was due to a decrease in minute ventilation resulting from a reduction in ventilation drive as reflected in blunted ventilatory responses to CO 2 produced by GABA B agonism, as found in animals [5, 6] . Intrathecal baclofen (162-237 μg/day, concentration 500 μg/ml) in patients with severe spasticity induced a significant increase in central sleep apnea after a drug bolus administration but not during continuous administration [7] . It was hypothesized that -as opposed to continuous administration -a direct effect of a bolus administration of baclofen on the central ventilatory drive may explain these observations. The oral intake may have been high enough here to trigger the same effect. Such a reduction in ventilatory drive, related to the inhibition of both resting ventilation and the slope of the ventilatory response to CO 2 , may be analogous to the inhibition of cardiovascular centers when GABA is administered at the ventral brainstem level [8] . It was also reported that intoxication with a high dose of baclofen induced a decrease in respiratory rate and coma, probably by directly depressing spinal cord inspiratory neurons [9] . It therefore appears that the pathophysiology of baclofen-related central sleep apnea differs from that suggested for patients with heart failure [10, 11] . This is of importance as the management of drug-induced CSAS may include adap- tive servoventilation, a treatment that is contraindicated in central sleep apnea associated with heart failure since the recent release of results of a large clinical trial [12] . This is a significant concern, as baclofen is increasingly used in the management of AUD. In fact, several reports have strongly suggested that baclofen can be efficiently used for alcohol withdrawal syndrome in humans [13] [14] [15] [16] . In addition, it has been shown that highdose baclofen (75-400 mg/day) achieves and maintains alcohol abstinence and reduces craving for alcohol [14] [15] [16] . It is, however, noteworthy that not all randomized, placebo-controlled studies support the efficacy of baclofen in AUD [17] . Thus, baclofen has not yet been recommended in Europe or in the USA for the treatment of AUD (DSM-5). However, its off-label administration has progressively emerged and, without any official approval or guidelines about its use, arbitrary prescription practices have developed. French alcohol specialists currently prescribe baclofen to almost 100,000 AUD sufferers, typically at off-label high doses [18] . This practice may spread in the future, as it has already been reported in other European countries, Australia and in the USA.
This case report illustrates the deleterious effect of baclofen on breathing physiology during sleep. Since it is typically prescribed off label at high doses to a population of patients potentially using other substances that already inhibit the ventilatory drive (i.e. alcohol or benzodiazepines), this possible adverse effect is of major concern. When considering the use of baclofen in patients with AUD, the potential for sleep-disordered breathing should be weighed and carefully monitored. Further studies are needed to confirm the direct causal relationship between baclofen and CSAS.
